Aidea Pharma(SH:688488) Zheng Quan Shi Bao Wang·2025-07-06 13:24Core Viewpoint - The National Medical Products Administration (NMPA) has released the "Guidelines for Clinical Resistance Research and Data Submission for Anti-HIV Drugs," establishing a standardized benchmark for HIV drug development in China [2][3]. Group 1: Regulatory Changes - The new guidelines aim to address the urgent issue of HIV drug resistance, which poses significant challenges to treatment efficacy and public health [4]. - The guidelines introduce stricter requirements for drug development, raising the bar for the industry and encouraging companies to develop safer and more effective new drugs [4][5]. Group 2: Company Involvement - Aidi Pharmaceutical, a leading company in the anti-HIV field, actively participated in the formulation of these guidelines, sharing its extensive experience in resistance research [5][6]. - The company has been recognized for its commitment to tackling HIV challenges and has contributed valuable insights during the guideline consultation process [5][6]. Group 3: Research and Development - Aidi Pharmaceutical's existing drugs, such as Ainovelin and Ainomir, have shown excellent clinical performance with low cross-resistance to previous non-nucleoside drugs, providing effective treatment options for patients [7]. - The company is also developing a new integrase inhibitor, ACC017, which has shown promising results in early clinical trials, indicating good safety and efficacy profiles [8]. Group 4: Future Directions - Aidi Pharmaceutical plans to continue increasing its R&D investments and enhancing its innovation capabilities in response to the new guidelines, aiming to develop more high-quality anti-HIV drugs [9]. - The company emphasizes the importance of resistance research in drug development and aims to contribute significantly to China's HIV prevention and treatment efforts [9].